At the Annual General Meeting of Hempel A/S on 2 May 2024, Britt Meelby Jensen will be put forward for election as member of the Board of Directors.

As CEO of Ambu A/S, Jensen comes with extensive experience from the life science industry, where she has served in various leadership roles in global companies for more than two decades. From 2019, Jensen was CEO of Swedish Atos Medical until she led the sale of the company to Coloplast in early 2022.

From 2015 to 2019, Jensen was CEO of Zealand Pharma. Prior to this, Jensen served as CEO of Dako and held several leadership positions in Novo Nordisk.

Britt Meelby Jensen has been a board member of the Hempel Foundation and Hempel Invest A/S since 2018. Once elected for the Hempel A/S Board of Directors, Jensen will step down as board member of the Hempel Foundation and Hempel Invest A/S.

“I am thrilled that Britt Meelby Jensen has accepted to be nominated for the Hempel A/S Board of Directors. With more than 20 years’ experience within healthcare and general management, alongside her contribution to the Hempel Foundation board and the Hempel Invest A/S board, we are convinced that Britt Meelby Jensen is the right profile to join the Hempel A/S Board of Directors,” said Richard Sand, chairman of the Board of Directors of Hempel A/S.

Jensen replaces Susanna Schneeberger on the Hempel A/S board. Schneeberger has served on the board since 2018 and has made outstanding contributions in developing Hempel A/S into a growing global enterprise.

“On behalf of the Board of Directors, I would like to take this opportunity to thank Susanna Schneeberger for her very valuable contribution to the Hempel Group over the past six years,” said Sand.